Article
Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation.
Cancer biology & therapy - 1 Oct 2008
Park Margaret A, Zhang Guo, Martin Aditi Pandya, Hamed Hossein, Mitchell Clint, Hylemon Philip B, Graf Martin, Rahmani Mohamed, Ryan Kevin, Liu Xiang, Spiegel Sarah, Norris James, Fisher Paul B, Grant Steven, Dent Paul
Abstract excerpt
We recently noted that low doses of sorafenib and vorinostat interact in a synergistic fashion to kill carcinoma cells by activating CD95, and this drug combination is entering phase I trials. The present studies mechanistically extended our initial observations. Low doses of sorafenib and vorinostat, but not the individual agents, caused an acidic sphingomyelinase and fumonisin B1-dependent increase in CD95...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
